Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology announced that CEO Marianne De Backer will present at the Jefferies 2026 London Healthcare Conference on November 18. The presentation is scheduled for 10:30 a.m. GMT / 5:30 a.m. ET. A live webcast will be available and archived for 30 days, enhancing accessibility for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Marianne De Backer will present at a major healthcare conference.
  • The event provides visibility for Vir Biotechnology.
  • A live webcast will be available for broader audience access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2026 London Healthcare Conference on Wednesday, November 18 at 10:30 a.m. GMT / 5:30 a.m. ET in London, United Kingdom.A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stag

Frequently Asked Questions

When will Vir Biotechnology present at the conference?

Vir Biotechnology will present on November 18 at 10:30 a.m. GMT.

Who will represent Vir Biotechnology at the conference?

CEO Marianne De Backer will represent the company.

Will the presentation be available online?

Yes, a live webcast will be available and archived for 30 days.

Where is the Jefferies 2026 Conference held?

The conference is held in London, United Kingdom.

ShareAdd on Google
Tags: VIR Vir Biotechnology Jefferies 2026 London Healthcare Conference Marianne De Backer investor presentation
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$529M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →